Moderna - A Step Closer To Coronavirus Vaccine: ETFs To Gain

The first company to start human clinical trials of its coronavirus vaccine candidate in the United States — Moderna (MRNA) — has informed that it is on schedule to initiate the final-stage clinical trial by July. The last stage that will be arranged in partnership with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) would involve 30,000 participants in the United States and use a 100-microgram dose of the vaccine. 

The company also informed that the trial’s primary aim is to prevent the spread of coronavirus. The trial’s secondary goals will involve the prevention of severe cases of the disease that might result in hospitalization for management, and prevention of infection by SARS-CoV-2 — the virus responsible for causing COVID-19. Buoyed by the news, Moderna’s stock rose 0.2% on June 11, when the S&P 500 lost 5.9% on rising worries over the resurgence of coronavirus infections in the United States.

Investors are starting to increasingly worry about the rising number of coronavirus cases in around 20 states in the United States. Going by the Johns Hopkins University data, the number of U.S. coronavirus infections passed the grim mark of two million, and more than 113,700 Americans have lost their lives. The seven-day average of new cases continued to spike in more than 20 states in the last two weeks, despite a lesser number of cases being recorded in some cities and states.

Other Vaccine Candidates Also Seeing Progress

Johnson & Johnson (JNJ) announced that it is speeding up the timeline for the initiation of a phase I/II human clinical study on its vaccine candidate for COVID-19. It will now begin the phase I/II study in the second half of July rather than September, as announced earlier.

Strong preclinical data and positive feedback from regulatory authorities allowed J&J to accelerate the clinical study on the COVID-19 vaccine candidate, Ad26.COV2-S, recombinant. J&J’s goal is to supply more than 1 billion doses of the vaccine globally, if it proves to be safe and effective.

1 2
View single page >> |

 Related articles include:  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.